Skip to main content

ACNS1833 A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibr

NCT04166409

A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

Associated Conditions

Brain Cancer

Principal Investigator

Sponsor

Children's Oncology Group

This study looks at how well a drug called selumetinib works when given to children and young adults with LGG. The study doctors want to see if selumetinib works as well as CV for getting rid of or shrinking LGGs and stopping them from coming back. They also want to know if this treatment will improve quality of life for subjects who take it. The overall goal of this study is to see if selumetinib works just as well as the standard treatment of CV for subjects with LGG.

This study is currently enrolling.